Cystic fibrosis in the era of genomic medicine

Current Opinion in Pediatrics

Volumn 25, Issue 3, 2013, Pages 323-328

  Milla, Carlos E ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

CF airway microbiology; CF correctors and potentiator therapies; Early lung disease

Indexed keywords

ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; RESPIRATORY TRACT AGENT; UNCLASSIFIED DRUG; VX 661;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CELL ASSAY; CLINICAL FEATURE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; GENE MUTATION; GENOME ANALYSIS; GENOMICS; HUMAN; MICROBIOME; NONHUMAN; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PREMATURE TERMINATION CODON; PRIORITY JOURNAL; REVIEW; STOP CODON;

AMINOPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; QUINOLONES; RESPIRATORY TRACT INFECTIONS;

EID: 84879893299     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328360dbf5     Document Type: Review

References (82)

1. Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature 2003; 422:835-847.
2. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921.
3. Watson JD, Crick FHC. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 1953; 171:737-738.
4. Guttmacher AE, Collins FS. Genomic medicine - a primer. N Engl J Med 2002; 347:1512-1520.
5. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148:1293-1307.
6. Bedrossian C, Greenberg S, Singer D, et al. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976; 7:195-204.
7. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995; 310:1571-1572.
8. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151:1075-1082.
9. Nixon GM, Armstrong DS, Carzino R, et al. Early airway infection, inflammation, and lung function in cystic fibrosis. Arch Dis Child 2002; 87:306-311.
10. Dakin CJ, Numa AH, Wang H, et al. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002; 165:904-910.
11. Ranganathan SC, Parsons F, Gangell C, et al. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax 2011; 66:408-413.
12. Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180:146-152.
13. Pillarisetti N, Williamson E, Linnane B, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184:75-81.
14. Ostedgaard LS, Meyerholz DK, Chen J-H, et al. The DF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs. Sci Transl Med 2011; 3:74ra24.
15. Rogers CS, Stoltz DA, Meyerholz DK, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008; 321:1837-1841.
16. Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010; 2:29ra31.
17. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487:109-113.
18. Poulsen JH, Fischer H, Illek B, Machen TE. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA 1994; 91:5340-5344.
19. Smith JJ, Welsh MJ. cAMP stimulates bicarbonate secretion across normal, but not cystic fibrosis airway epithelia. J Clin Investig 1992; 89:1148-1153.
20. Chang EH, Pezzulo AA, Meyerholz DK, et al. Sinus hypoplasia precedes sinus infection in a porcine model of cystic fibrosis. Laryngoscope 2012; 122:1898-1905.
21. Hansen SK, Rau MH, Johansen HK, et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 2012; 6: 31-45.
22. Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008; 178:1238-1244.
23. Ranganathan SC, Dezateux C, Bush A, et al. Airway function in infants newly diagnosed with cystic fibrosis. Lancet 2001; 358:1964-1965.
24. Davis SD, Rosenfeld M, Kerby GS, et al. Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. Am J Respir Crit Care Med 2010; 182:1387-1397.
25. Harrison AN, Regelmann WE, Zirbes JM, Milla CE. Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44:330-339.
26. Aurora P, Stanojevic S, Wade A, et al. Lung Clearance Index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2011; 183:752-758.
27. Hoo AF, Thia LP, Nguyen TT, et al. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. Thorax 2012; 67:874-881.
28. Lum S, Gustafsson P, Ljungberg H, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 2007; 62:341-347.
29. Belessis Y, Dixon B, Hawkins G, et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and Lung Clearance Index. Am J Respir Crit Care Med 2012; 185:862-873.
30. Gustafsson PM. Inert gas washout in preschool children. Paediatr Respir Rev 2005; 6:239-245.
31. Gustafsson PM, De Jong PA, Tiddens HA, Lindblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 2008; 63:129-134.
32. Owens CM, Aurora P, Stanojevic S, et al. Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF. Thorax 2011; 66:481-488.
33. Stick SM, Brennan S, Murray C, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009; 155:623-628; e621.
34. Mott LS, Park J, Murray CP, et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012; 67:509-516.
35. Ramsey BW, Banks-Schlegel S, Accurso FJ, et al. Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report. Am J Respir Crit Care Med 2012; 185:887-892.
36. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373:1891-1904.
37. Registry CFFP. 2011 Annual Data Report to the Center Directors. Bethesda, MD: CF Foundation; 2012.
38. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011; 24:29-70.
39. Folkesson A, Jelsbak L, Yang L, et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol 2012; 10:841-851.
40. Rogers GB, Hoffman LR, Dö ring G. Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. J Cyst Fibros 2011; 10:387-400.
41. Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123:1495-1502.
42. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology 2007; 153:917-923.
43. Rogers G, Carroll M, Bruce K. Studying bacterial infections through culture-independent approaches. J Med Microbiol 2009; 58:1401-1408.
44. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23:299-323.
45. Rogers G, Skelton S, Serisier D, et al. Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2010; 48:78-86.
46. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486:207-214.
47. Kolak M, Karpati F, Monstein H, Jonasson J. Molecular typing of the bacterial flora in sputum of cystic fibrosis patients. Int J Med Microbiol 2003; 293:309-317.
48. Rogers G, Hart C, Mason J, et al. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2003; 41:3548-3558.
49. Rogers G, Carroll M, Serisier D, et al. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16 s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004; 42:5176-5183.
50. Rogers G, Carroll M, Serisier D, et al. Bacterial activity in cystic fibrosis lung infections. Respir Res 2005; 6:49.
51. Rogers G, Carroll M, Serisier D, et al. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol 2006; 44:2601-2604.
52. Harris JK, De Groote MA, Sagel SD, et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 2007; 104:20529-20533.
53. Armougom F, Bittar F, Stremler N, et al. Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing. Eur J Clin Microbiol Infect Dis 2009; 28:1151-1154.
54. Guss A, Roeselers G, Newton I, et al. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J 2011; 5:20-29.
55. Cox MJ, Allgaier M, Taylor B, et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE 2010; 5:e11044.
56. Klepac-Ceraj V, Lemon KP, Martin TR, et al. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 2010; 12:1293-1303.
57. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011; 184:957-963.
58. Blainey PC, Milla CE, Cornfield DN, Quake SR. Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis. Sci Transl Med 2012; 4:153ra130.
59. Delhaes L,Monchy S, Frealle E, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community - implications for therapeutic management. PLoS one 2012; 7:e36313.
60. Willner D, Haynes MR, Furlan M, et al. Spatial distribution of microbial communities in the cystic fibrosis lung. ISME J 2012; 6:471-474.
61. Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012; 109:5809-5814.
62. Madan JC, Koestler DC, Stanton BA, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. mBio 2012; 3:e00251-12.
63. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363:1991-2003.
64. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663-1672.
65. Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106:18825-18830.
66. González JE, Oades K, Leychkis Y, et al. Cell-based assays and instrumentation for screening ion-channel targets. Drug Discov Today 1999; 4:431-439.
67. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73:1251-1254.
68. Van Goor F, Straley KS, Cao D, et al. Rescue of DF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290:L1117-L1130.
69. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115:2564-2571.
70. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective DF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67:1797-1807.
71. Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective DF508-CFTR chloride channel gating. J Biol Chem 2003; 278:35079-35085.
72. Van Goor F, Hadida S, Grootenhuis PDJ, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011; 108:18843-18848.
73. Rabeh WM, Bossard F, Xu H, et al. Correction of both NBD1 energetics and domain interface is required to restore F508 CFTR folding and function. Cell 2012; 148:150-163.
74. Mendoza JL, Schmidt A, Li Q, et al. Requirements for efficient correction of F508 CFTR revealed by analyses of evolved sequences. Cell 2012; 148:164-174.
75. Hudson RP, Chong PA, Protasevich II, et al. Conformational changes relevant to channel activity and folding within the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 2012; 287:28480-28494.
76. Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the F508 conformational defect. Trends Mol Med 2012; 18:81-91.
77. Boyle MP, Bell S, Konstan MW, et al. The investigational CFTR corrector, VX-809 (Lumacaftor) co-administered with the oral potentiator Ivacaftor improved CFTR and lung function in F508del homozygous patients: phase II study results. Pediatr Pulmonol 2012; S35:315.
78. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372:719-727.
79. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011; 38:59-69.
80. Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010; 182:1262-1272.
81. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11:237-245.
82. Yarlagadda S, Zhang W, Penmatsa H, et al. A young Hispanic with c.1646G>A mutation exhibits severe cystic fibrosis lung disease: is ivacaftor an option for therapy? Am J Respir Crit Care Med 2012; 186:694-696.